SCHEMBL4664338

SCHEMBL4664338

CCN(CC)c1ccc2nc3c4ccc(O)cc4c(=O)c(Br)c-3oc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.52
KMT2A Q03164 9/20 0.52
POLB P06746 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
ALDH1A1 P00352 12/20 0.44
KDM4E B2RXH2 10/20 0.44
MAPT P10636 9/20 0.44
GLA P06280 7/20 0.44
ATM Q13315 6/20 0.44
L3MBTL1 Q9Y468 5/20 0.44
HSD17B10 Q99714 5/20 0.44
CYP3A4 P08684 4/20 0.44
CYP1A2 P05177 4/20 0.44
CYP2C19 P33261 4/20 0.44
CASP1 P29466 4/20 0.44
CASP7 P55210 4/20 0.44
HTT P42858 4/20 0.44
TDP1 Q9NUW8 3/20 0.44
ALOX15 P16050 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14267412 0.96 MEN1 (0.49) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL15398240 0.87 MEN1 (0.64) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL4663120 0.85 MEN1 (0.48) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL14267413 0.84 MEN1 (0.49) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL14267415 0.84 SCP2 (0.56) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL14289862 0.82 KDM4E (0.39) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL4664437 0.80 MEN1 (0.76) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL56792 0.78 MEN1 (0.76) MEN1KMT2APOLBNPC1RAB9A
SCHEMBL14289870 0.78 KDM4E (0.39) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL4664473 0.78 SCP2 (0.72) MEN1KMT2APOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080038840-A1 Fluorescent Method And Compounds To Monitor Protein-Lipid Binding EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) 2008-02-14 US disclosed
US-20080038840-A1 Fluorescent Method And Compounds To Monitor Protein-Lipid Binding EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) 2008-02-14 US disclosed
US-20080038840-A1 Fluorescent Method And Compounds To Monitor Protein-Lipid Binding EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE (DE) 2008-02-14 US disclosed
EP-1595872-A1 Fluorescent compounds for monitoring protein-lipid binding EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) 2005-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080038840-A1 Fluorescent Method And Compounds To Monitor Protein-Lipid Binding DBI, CETP, SREBF1 MEN1 3143/4885KMT2A 2814/4885POLB 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.